when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Genentech Inc · catalysts · pharmadog

← back to Genentech Inc

Catalysts for Genentech Inc

166 tracked

ITOVEBI (INAVOLISIB) — FDA approval

VABYSMO (FARICIMAB-SVOA) — FDA approval

KADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approval

trastuzumab emtansine

POLIVY (POLATUZUMAB VEDOTIN-PIIQ) — FDA approval

polatuzumab vedotin

EVRYSDI (RISDIPLAM) — FDA approval

EVRYSDI (RISDIPLAM) — FDA approval

EVRYSDI (RISDIPLAM) — FDA approval

EVRYSDI (RISDIPLAM) — FDA approval

EVRYSDI (RISDIPLAM) — FDA approval

LUNSUMIO (MOSUNETUZUMAB-AXGB) — FDA approval

GAZYVA (OBINUTUZUMAB) — FDA approval

ACTEMRA (TOCILIZUMAB) — FDA approval

ACTEMRA (TOCILIZUMAB) — FDA approval

TECENTRIQ HYBREZA (ATEZOLIZUMAB AND HYALURONIDASE-TQJS) — FDA approval

(atezolizumab + hyaluronidase (human recombinant))

TECENTRIQ (ATEZOLIZUMAB) — FDA approval

TECENTRIQ HYBREZA (ATEZOLIZUMAB AND HYALURONIDASE-TQJS) — FDA approval

(atezolizumab + hyaluronidase (human recombinant))

COLUMVI (GLOFITAMAB-GXBM) — FDA approval

GAZYVA (OBINUTUZUMAB) — FDA approval

GAZYVA (OBINUTUZUMAB) — FDA approval

TECENTRIQ (ATEZOLIZUMAB) — FDA approval

TECENTRIQ HYBREZA (ATEZOLIZUMAB AND HYALURONIDASE-TQJS) — FDA approval

(atezolizumab + hyaluronidase (human recombinant))

ITOVEBI (INAVOLISIB) — FDA approval

TECENTRIQ (ATEZOLIZUMAB) — FDA approval

TECENTRIQ HYBREZA (ATEZOLIZUMAB AND HYALURONIDASE-TQJS) — FDA approval

(atezolizumab + hyaluronidase (human recombinant))

ACTEMRA (TOCILIZUMAB) — FDA approval

ACTEMRA (TOCILIZUMAB) — FDA approval

COLUMVI (GLOFITAMAB-GXBM) — FDA approval

KADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approval

trastuzumab emtansine

EVRYSDI (RISDIPLAM) — FDA approval

EVRYSDI (RISDIPLAM) — FDA approval

← prevpage 1 of 6next →